Evolocumab in treatment of acute pancreatitis induced by hypertriglyceridemia
Acute pancreatitis (AP) is a common emergency resulting from inflammation of the pancreas. The mechanism involves premature activation of enzyme precursors in the acinar cells triggering a self-digestive inflammatory cascade. Hypertriglyceridemia is the most common etiology of pancreatitis after gall stones and alcohol. It usually follows a sudden surge such as diabetic ketoacidosis on top of hereditary hyperlipidemia. In the present case report; we describe a patient with type-I diabetes mellitus who had developed recurrent attacks of hypertriglyceridemia AP (HTG-AP) despite Fenfibrate-therapy and report on our experience with Evolocumab in his treatment and prophylaxis.
Keywords: diabetes mellitus, hypertriglyceridemia, pancreatitis, prophylaxis, treatment.
2- Dominguez-Munoz JE, Malfertheiner P, Ditschuneit HH, Blanco-Chavez J, Uhl W, Buchler M, et al. Hyperlipidemia in acute pancreatitis. Relationship with etiology, onset and severity of the disease. Int J Pancreatol 1991; 10:261–267.
3- Whitcomb DC, Yadav D, Adam S, et al. North American Pancreatic Study Group. Multicenter approach to recurrent acute and chronic pancreatitis in the United States: the North American Pancreatitis Study 2 (NAPS2). Pancreatology 2008; 8:520–531.
4- Seales CE, Ooi TC. Underrecognition of chylomicronemia as a cause of acute pancreatitis. CMAJ 1992; 147:1806–1808.
5- Fredrickson, DS; Lees, RS (1965). A system for phenotyping hyperlipoproteinemia. Circulation 1965; 31:321–327
6- Lithell H, Vessby B, Walldius G, Carlson LA. Hypertriglyceridemia-acute pancreatitis-ischemic heart disease. A case study in a pair of monozygotic twins. Acta Med Scand 1987; 221:311–316.
7- Kimura W, Mossner J. Role of hypertriglyceridemia in the pathogenesis of experimental acute pancretitis in rats. Int J Pancreatol 1996; 20:177–184
8- Smotkin J, Tenner S. Laboratory diagnostic tests in acute pancreatitis. J Clin Gastroenterol 2002; 34:459–462.
9- Joshua A, Greenberg JA, Hsu J. Bawazeer M, Marshall J, Friedrich JO, Cobrun N, May GR, Pearsall E, McLead RS. Clinical practice guideline: management of acute pancreatitis. Can J Surg 2016; 59:128–140.
10- Rubins HB, Robins SJ, Collins D, Nelson DB, Elam MB, Schaefer EJ, et al. Diabetes, plasma insulin and cardiovascular disease: Subgroup analysis from the Department of Veterans Affairs high density lipoprotein intervention trial (VA-HIT) Arch Intern Med 2002; 162: 2597–2604.
11- Frick MH, Elo O, Haapa K, Heinonen OP, Heinsalmi P, Helo P, et al. Helsinki Heart Study: Primary-prevention trial with gemfibrozil in middle aged men with dyslipidemia. Safety of treatment, changes in risk factors and incidence of coronary heart disease. N Engl J Med 1987; 317:1237–1245.
12- Yeh JH, Chen JH, Chiu HC. Plasmapheresis for hyperlipidemic pancreatitis. J Clin Apheresis 2003; 18:181–185
13- Weinreich, M; Frishman, W. "Antihyperlipidemic therapies targeting PCSK9". Cardiology in Review 2014; 22:140–6.
14- FDA News Release (August 27, 2015). FDA approves Repatha to treat certain patients with high cholesterol. U.S. Food and Drug Administration. Retrieved 30 August 2015.
15- Sabatine MS, Giugliano RP, Keech, AC, Honarpour N, Wiviott SD, Murphy SA, Kuder JF, Wang H, Liu T. "Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. N England J Med 2017; 376:1713–1722.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).